α1-antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 8, 2014, Pages

  Gottlieb, Peter A ^a   Alkanani, Aimon K ^a   Michels, Aaron W ^a   Lewis, Eli C ^c   Shapiro, Leland ^d   Dinarello, Charles A ^b   Zipris, Danny ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ALPHA 1-ANTITRYPSIN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; DOWN-REGULATION; FEMALE; HUMANS; INTERLEUKIN-1BETA; ISLETS OF LANGERHANS; MALE; MONOCYTES; MYELOID CELLS; TOLL-LIKE RECEPTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905821474     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3864     Document Type: Article

References (40)

1. Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol Rev. 2005;204:232-249.
2. Dotta F, Censini S, van Halteren AG, et al. Coxsackie B4 virus infection ofβ-cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A. 2007;104(12):5115-5120.
3. Dotta F, Galleri L, Sebastiani G, Vendrame F. Virus Infections: Lessons from Pancreas Histology. Curr Diab ReP. 2010;10(5):357-361.
4. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia. 2009;52(6): 1143-1151.
5. Roep BO, Kleijwegt FS, van Halteren AG, et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin ExP Immunol. 2010;159(3):338-343.
6. Ylipaasto P, Klingel K, Lindberg AM, et al. Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet β-cells. Diabetologia. 2004;47(2):225-239.
7. Yoon JW, Austin M, Onodera T, Notkins AL. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med. 1979;300(21):1173-1179.
8. Tanaka S, Nishida Y, Aida K, et al. Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated β-cell failure in fulminant type 1 diabetes. Diabetes. 2009;58(10):2285-2291.
9. Breit SN, Wakefield D, Robinson JP, Luckhurst E, Clark P, Penny R. The role of α1-antitrypsin deficiency in the pathogenesis of immune disorders. Clin Immunol ImmunoPathol. 1985;35(3):363-380.
10. Janciauskiene S, Larsson S, Larsson P, Virtala R, Jansson L, Stevens T. Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by α1-antitrypsin. Biochem BioPhys Res Commun. 2004;321(3):592-600.
11. Pott GB, Chan ED, Dinarello CA, Shapiro L. α1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol. 2009;85(5):886-895.
12. Shapiro L, Pott GB, Ralston AH. α1-Antitrypsin inhibits human immunodeficiency virus type 1. FASEB J. 2001;15(1):115-122.
13. Koulmanda M, Bhasin M, Hoffman L, et al. Curative and β-cell regenerative effects of α1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A. 2008;105(42):16242-16247.
14. Ma H, Lu Y, Li H, et al. Intradermal α1-antitrypsin therapy avoids fatal anaphylaxis, prevents type 1 diabetes and reverses hyperglycaemia in theNODmouse model of the disease. Diabetologia. 2010; 53(10):2198-2204.
15. Lewis EC, Mizrahi M, Toledano M, et al. α1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci U S A. 2008;105(42):16236-16241.
16. Wolter TR, Wong R, Sarkar SA, Zipris D.DNAmicroarray analysis for the identification of innate immune pathways implicated in virus- induced autoimmune diabetes. Clin Immunol. 2009;132(1): 103-115.
17. Londono P, Komura A, Hara N, Zipris D. Brief dexamethasone treatment during acute infection prevents virus-induced autoimmune diabetes. Clin Immunol. 2010;135(3):401-411.
18. Hara N, Alkanani AK, Dinarello CA, Zipris D. Modulation of virusinduced innate immunity and type 1 diabetes by IL-1 blockade [published online September 23, 2013]. Innate Immun. doi:10.1177/1753425913502242.
19. Hara N, Alkanani A, Dinarello C, Zipris D. Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes. J Mol Med. 2013;1-10.
20. Alkanani AK, Rewers M, Dong F, Waugh K, Gottlieb PA, Zipris D. Dysregulated Toll-like receptor-induced interleukin-1β and interleukin- 6 responses in subjects at risk for the development of type 1 diabetes. Diabetes. 2012;61:2525-2533.
21. Meyers AJ, Shah RR, Gottlieb PA, Zipris D. Altered toll-like receptor signaling pathways in human type 1 diabetes. J Mol Med. 2010; 88(12):1221-1231.
22. Greenbaum CJ, Beam CA, Boulware D, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes. 2012;61(8):2066-2073.
23. Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK. Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children. Mediators Inflamm. 2006;2006(1):59206.
24. Erbaǧci AB, Tarakçioǧlu M, Coşkun Y, Sivasli E, Sibel Namiduru E. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clin Biochem. 2001; 34(8):645-650.
25. Nicoletti F, Conget I, Di Marco R, et al. Serum levels of the interferon- -inducing cytokine interleukin-18 are increased in individuals at high risk of developing type I diabetes. Diabetologia. 2001; 44(3):309-311.
26. Perez F, Oyarzun A, Carrasco E, Angel B, Albala C, Santos JL. Plasma levels of interleukin-1β, interleukin-2 and interleukin-4 in recently diagnosed type 1 diabetic children and their association with-pancreatic autoantibodies [in Spanish]. Rev Med Chil. 2004; 132(4):413-420.
27. Zipris D. Toll-like receptors and type 1 diabetes. Adv ExP Med Biol. 2010;654:585-610.
28. Zipris D. Innate immunity in type 1 diabetes. Diabetes Metab Res Rev. 2011;27(8):824-829.
29. Herold KC, Vignali DA, Cooke A, Bluestone JA. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol. 2013;13(4):243-256.
30. Sköld S, Rosberg B, Gullberg U, Olofsson T. A Secreted Proform of Neutrophil Proteinase 3 Regulates the Proliferation of Granulopoietic Progenitor Cells. Blood. 1999;93(3):849-856.
31. Sköld S, Zeberg L, Gullberg U, Olofsson T. Functional dissociation between proforms and mature forms of proteinase 3, azurocidin, and granzyme B in regulation of granulopoiesis. ExP Hematol. 2002;30(7):689-696.
32. Jonigk D, Al-Omari M, Maegel L, et al. Anti-inflammatory and immunomodulatory properties ofα1-antitrypsin without inhibition of elastase. Proc Natl Acad Sci U S A. 2013;110(37):15007-15012.
33. Subramaniyam D, Zhou H, Liang M, Welte T, Mahadeva R, Janciauskiene S. Cholesterol rich lipid raft microdomains are gateway for acute phase protein, SERPINA1. Int J Biochem Cell Biol. 2010; 42(9):1562-1570.
34. Ochayon DE, Mizrahi M, Shahaf G, Baranovski BM, Lewis EC. Human α1-antitrypsin binds to heat-shock protein gp96 and protects from endogenous gp96-mediated injury in vivo. Front Immunol. 2013;4:320-333.
35. Grant CW, Moran-Paul CM, Duclos SK, Guberski DL, Arreaza- Rubin G, SpainLM.Testing agents for prevention or reversal of type 1 diabetes in rodents. PLoS One. 2013;8(8):e72989.
36. Eizirik DL, Mandrup-Poulsen T.Achoice of death-the signal-transduction of immune-mediated β-cell apoptosis. Diabetologia. 2001; 44(12):2115-2133.
37. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia. 1996;39(9):1005-1029.
38. Pickersgill LM, Mandrup-Poulsen TR. The anti-interleukin-1 in type 1 diabetes action trial-background and rationale. Diabetes Metab Res Rev. 2009;25(4):321-324.
39. Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol. 2010;6(3): 158-166.
40. Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double- blind, placebo-controlled trials. Lancet. 2013;38(9881):1905- 1915.